Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Summary

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) and in combination with docetaxel and prednisone in participants with advanced solid tumors.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Renal Cell Carcinoma (RCC)
• Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Urothelial Carcinoma (UC)
• Solid Tumor
• Hepatocellular Carcinoma (HCC)
• Non-small Cell Lung Cancer (NSCLC)
• Colorectal Cancer (CRC)
• Head and Neck Squamous Cell Carcinoma (HNSCC)
• Clear Cell Renal Cell Carcinoma (ccRCC)
• Non-Clear Cell Renal Cell Carcinoma (nccRCC)
• Drug-Drug Interaction (DDI)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Exelixis

Last updated on ClinicalTrials.gov

October 1, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites